Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Publication|Articles|August 13, 2024
- Ophthalmology Times: August 2024
- Volume 49
- Issue 8
A clear path ahead
Author(s)Kathryn A. Colby, MD, PhD
Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.
Advertisement
Advertisement
Fuchs endothelial corneal dystrophy (FECD) is a common corneal disease that affects 4% to 7% of people in the US.1 FECD is a progressive dysfunction of the corneal endothelium characterized by abnormal endothelial morphology (pleomorphism and polymegethism) with an accumulation of guttae and excrescences on the Descemet membrane. Early disease is not typically symptomatic. Corneal edema occurs as the condition progresses, and patients may notice blurry vision, often more severe upon awakening.
Related to this article
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Advertisement
Advertisement